Australia · Delayed Price · Currency is AUD Integrated Research Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and earnings declined due to a softer renewals book and a large credit loss, but cash and net assets remain strong. Product-led growth advanced with new AI and SaaS offerings, and management is prioritizing investment in innovation over buybacks.
Fiscal Year 2025
-
The meeting highlighted disciplined financial management, a robust balance sheet, and a continued focus on product-led growth. New products like Prognosis Elevate and Iris were launched, with further innovation and medium-term growth expected as new offerings roll out in 2026.
-
FY 2025 saw revenue and profit declines due to lower renewals and expansion revenue, but new client revenue and product innovation showed early promise. Significant investment in product-led growth and AI is expected to dampen profits for two to three years as the company transitions to a more sustainable growth model.
-
New business revenue surged 76% year-over-year, offsetting some impact from a 36% drop in total contract value due to soft renewals. Pro forma revenue was stable, and a new High Value Payments product was launched with a major US bank as a client.
Fiscal Year 2024
-
The meeting highlighted strong financial recovery, a shift to a product-led growth strategy, and board refreshment. Dividend was declared, and innovation, new product development, and disciplined capital management were emphasized. Shareholders engaged on remuneration, M&A, and operational strategy.
-
FY 2024 saw 19% revenue growth, strong cash generation, and a turnaround in the Americas, despite ongoing churn in Collaborate. FY 2025 will focus on larger enterprise customers, product-led growth, and balanced capital allocation, with churn and market shifts remaining key risks.